Antibodies

Items 911-920 of 1041

per page
Set Descending Direction
  1. anti-p53 (human), mAb (Pab240) (Biotin)
    ANC-227-030.
    ANC-227-030100 µg
    CHF 306.00
  2. anti-p53 (human), mAb (Pab240) (FITC)
    ANC-227-040.
    ANC-227-040120 tests
    CHF 306.00
  3. anti-PD-1 (mouse), mAb (blocking) (1H10)
    AG-20B-0075
    AG-20B-0075-C100100 µg
    CHF 230.00
    anti-BAFF (mouse), mAb (Sandy-2) (Prod. No. AG-20B-0063) blocks the action of endogenous BAFF in vivo.  Method: Wild type C57BL/6 mice were treated at day 0 (single administration) with monoclonal antibody anti-BAFF (mouse), mAb (Sandy
  4. anti-PD-1 (mouse), mAb (blocking) (1H10) (preservative free)
    AG-20B-0075PF
    AG-20B-0075PF-C100100 µg
    CHF 230.00
    AG-20B-0075PF-C500500 µg
    CHF 400.00
    AG-20B-0075PF-M0022 mg
    CHF 590.00
    anti-BAFF (mouse), mAb (Sandy-2) (Prod. No. AG-20B-0063) blocks the action of endogenous BAFF in vivo.  Method: Wild type C57BL/6 mice were treated at day 0 (single administration) with monoclonal antibody anti-BAFF (mouse), mAb (Sandy
  5. anti-Perforin (human), mAb (δG9)
    ANC-358-020.
    ANC-358-020100 µg
    CHF 306.00
  6. anti-Perforin (human), mAb (δG9) (Biotin)
    ANC-358-030.
    ANC-358-030100 µg
    CHF 423.00
  7. anti-Perforin (human), mAb (δG9) (FITC)
    ANC-358-040.
    ANC-358-040120 tests
    CHF 423.00
  8. anti-Perforin (human), mAb (δG9) (R-PE)
    ANC-358-050.
    ANC-358-050120 tests
    CHF 455.00
  9. anti-Perforin (human), mAb (deltaG9) (APC)
    ANC-358-060.
    ANC-358-060120 tests
    CHF 683.00
    anti-Perforin (human), mAb (deltaG9) (APC)
  10. anti-Phosphothreonine, Rabbit Monoclonal (RM102)
    REV-31-1009-00
    REV-31-1009-00-C100100 µg
    CHF 528.00
    Immunocytochemistry of serum-starved A431 cells nontreated or treated with Calyculin A/ Okadaic Acid, using RevMAb Clone RM102 at 1/500 dilution (followed by PE conjugated secondary antibody, red) and DAPI (blue).

Items 911-920 of 1041

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.